Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain

Sara Domínguez-Rodríguez†,‡, Luis Prieto§, Carolina Fernández McPhee†, Marta Illán-Ramos‡, José Beciero§, Luis Escosa§, Eloy Muñoz†, Iciar Olabarrieta§, Francisco Javier Regidor§, Miguel Ángel Roa§, María del Carmen Viñuela Beneítez†, Sara Guillén§, María Luisa Navarro-Gómez‡, José Tomás Ramos Amador‡, on behalf of the Madrid Cohort of HIV-infected mother-infant pairs

1 Hospital Universitario 12 Octubre, Madrid, Spain, 2 Fundación SEIMC-GESIDA, Madrid, Spain, 3 Hospital General Universitativo Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, (IISSGM), CoRISpe, Spain Universidad Complutense, Madrid, Spain, 4 Hospital Clínico San Carlos, Madrid, Spain, 5 Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 6 Servicio de pediatría hospitalaria, enfermedades infecciosas y tropicales, Instituto de Investigación ICIIPAZ, Hospital Universitario La Paz, Madrid, Spain, 7 Red de Investigación Translacional en Infectología Pediátrica (RITIP), Madrid, Spain, 8 Hospital General de Móstoles, Móstoles, Spain, 9 Hospital de Getafe, Getafe, Spain

‡ These authors share first authorship on this work.
¶ Membership of the Termite Genome Working Group is listed in the Acknowledgments.
* marisa.navarro.gomez@gmail.com (MLNG); sara.dominguez.r@gmail.com (SDR)

Abstract

Background
Maternal HIV coinfection is a key factor for mother-to-child transmission (MTCT) of HCV. However, data about HCV MTCT in HIV/HCV-coinfected pregnant women on combined antiretroviral treatment (ART) are scarce. This study assessed the HCV MTCT rate in the Madrid Cohort of HIV-infected women.

Methods
Retrospective study within the Madrid Cohort of HIV-infected pregnant women (2000–2012). Epidemiological, clinical and treatment related variables were analysed for the mother and infant pairs. HCV MTCT rate was determined.

Results
Three hundred thirty-nine HIV/HCV-coinfected women and their exposed infants were recorded. A total of 227 (67%) paired mother-children had available data of HCV follow-up and were included for the analysis. Sixteen children (rate 7.0%, 95%CI 3.7–10.4%) were HCV infected by 18 months of age, none of them coinfected with HIV. HIV/HCV-coinfected pregnant women were mostly of Spanish origin with a background of previous injection drug use. HCV-genotype 1 was predominant. The characteristics of mothers that transmitted HCV were similar to those that did not transmit HCV with respect to sociodemographic and clinical features. A high rate (50%) of preterm deliveries was observed. Infants infected with HCV were similar at birth in weight, length and head circumference than those uninfected.
Conclusion

MTCT rates of HCV among HIV/HCV-coinfected women on ART within the Madrid cohort were lower than previously described. However, rates are still significant and strategies to eliminate any HCV transmission from mother to child are needed.

Introduction

Hepatitis C virus (HCV) infection has been recognised as a worldwide health problem in both adults and children, being the most common cause of chronic liver disease [1,2]. It is estimated that 5 million children worldwide have an active HCV infection [3].

After the implementation of universal testing of blood transfusion products, mother-to-child transmission (MTCT) became the leading source of HCV infection in children [1,4]. MTCT rates of HCV ranged from 3 to 8% with a weighted rate of transmission of 1.7% when the mother was anti-HCV positive, 4.3% when the mother was positive for HCV RNA, and up to 19.4% when the mother was coinfected with human immunodeficiency virus (HIV)[1,3–7]. The potential biological mechanisms responsible for this association are not yet clearly understood. HIV infection could play a role in the elevation of HCV load facilitating viral transmission, hepatic inflammation, prematurity or severity liver disease [8]. Polis et al. showed in 2007 that maternal HIV/HCV-coinfection increases the MTCT risk of HCV compared with maternal HCV infection alone [9]. More recent studies have confirmed HIV/HCV-coinfection as a potential HCV MTCT risk [6,7,10]. Benova et al. reported in a metaanalysis a HCV MTCT rate of 5.8 (95% CI 4.2–7.8) in monoinfected pregnant women, whereas the transmission rate from HIV/HCV-coinfected pregnant women was 10.8% (7.6–15.2%) [11].

However, many of these studies were performed before the combined antiretroviral therapy (ART) era, when women were more likely to be immunocompromised during pregnancy. Although antiretroviral therapy has no direct effect on HCV replication, the improved immunological condition or other unknown factors might contribute to a reduction of the vertical transmission rate reported in the natural history of the disease.

Fewer studies have examined the rates of MTCT of HCV among HIV-coinfected women with well-controlled HIV disease. In a previous study among HIV/HCV-coinfected mothers from Latin American and the Caribbean, a rate of MTCT of HCV of 8.5% (95% CI, 2.8–21.3) was observed [12]. This rate is similar to the rates of MTCT of HCV observed in multicenter studies conducted among HIV-uninfected women [13, 14].

Therefore, HCV MTCT among HIV/HCV coinfected women on stable antiretroviral treatment may be lower than reported in other coinfected population, presenting current rates of MTCT of HCV that are similar to those monoinfected. The primary objective of this study was to assess the MTCT rate of HCV among HCV/HIV-coinfected women, among infants with follow up testing available, in the ART era in Madrid, Spain.

Methods

Design

This was a retrospective study within the Madrid cohort of HIV-infected pregnant women from 2000 to 2012. The Madrid Cohort of HIV-infected mother-infant pairs is a multicenter, prospective and observational study of HIV-1 infected women and their children. Since 2000, mother and infants pairs have been recruited from 8 hospitals in Madrid. The characteristics
of the Madrid Cohort have been previously described elsewhere [15]. All HIV/HCV-coinfected pregnant women from the cohort were included in the study (n = 339) and epidemiological, clinical and treatment-related variables were collected during the gestational and delivery period. All children were followed prospectively from birth as part of the Madrid Cohort of mother-infant pairs. Data collection and information available workflow are summarized in S1 Fig. A total of 227 (66.8%) paired mother and children with available data from HCV diagnostic tests (serology and molecular) were analysed. Mother-infant pairs without available information (n = 112) about HCV serology or PCR in children were compared with those included in the study (S1 Table). In this cohort, HCV PCR was performed per protocol at 3–6 months and HCV serology from 12–18 months of age, simultaneously to HIV serology. Absence of HCV infection was considered as both HCV negative and negative PCR in the first eighteen months. Infants were considered to be HCV-infected if HCV PCR was detected in at least 1 sample and they had persistence of HCV antibodies after 18 months of age. Infants with HCV RNA-positive samples followed by subsequent HCV RNA-negative results at the 6-month visit were classified as having transient HCV infection. Two comparisons were performed: mothers who had transmitted HCV to their infants (n = 16) versus mothers who had not (n = 211), and children with HCV infection (n = 16) versus non-infected (n = 211).

Written informed consent was obtained for all mother-infant pairs. This study was reviewed and approved by the Ethics Committee from Hospital Universitario de Getafe, Madrid.

Statistical analysis
Chi-squared and Fisher tests were applied to assess differences among the groups for categorical variables. For continuous variables, Student t-test and U-Mann Whitney were applied when appropriate. To estimate the effect of the different sociodemographic, epidemiological and clinical-virological variables, odds ratios (ORs) were calculated and 95% confidence intervals (95% CIs) were assessed using logistic regression. Statistical analysis and graphs were performed using R Software (R Core Team (2018), version 3.5.2, Vienna, Austria. [16].

Results
Study population
All HIV/HCV-coinfected mothers from the Madrid cohort of HIV-infected pregnant women were included. A total of 227 paired mother and children were studied. HIV/HCV-coinfected mothers not included in the study due to absence of HCV diagnosis information, had lower HCV VL during pregnancy and were exposed to more rates of ART, compared to the HIV/HCV-coinfected mothers studied (S1 Table).

Mother’s characteristics
The studied population was mainly from Spain 202/227 (88.9%), Caucasian 206/227 (90.7%), and mostly HIV-infected by parenteral drug use (IVDU) 148/227 (65.2%) and sexual transmission 58/227 (25.5%). Mothers that gave birth to HCV infected children were similar in terms of sociodemographic characteristics, with respect to the non-HCV transmitters. Both groups had similar age at delivery (34 [30–37] vs. 34 [31.5–36.5] years) and gestational age (38 [36–38] vs. 37.5 [36.8–39] weeks), with almost 50% of preterm births in both groups (Table 1).

Analysing the immunologic and virologic status, HCV transmitters mother presented a slightly lower measurement of CD4 and higher HIV viral load than the non-HCV transmitters mothers. However, these differences did not reach statistical significance (Fig 1).
| Table 1. Characteristics of HIV/HCV-coinfected pregnant women according to the transmission of HCV to their infants. |
|--------------------------------------------------|--------------------------------------------------|------------------|
| **Sociodemographic**                              | **Non-HCV transmitters N = 211**                  | **HCV transmitters N = 16** | **p-value** |
| **Origin**                                        |                                                  |                               |              |
| Argentina                                        | 1 (0.52%)                                       | 0 (0.00%)                     | 1.000        |
| Chile                                            | 1 (0.52%)                                       | 0 (0.00%)                     |              |
| Colombia                                         | 1 (0.52%)                                       | 0 (0.00%)                     |              |
| Russia                                           | 2 (1.04%)                                       | 0 (0.00%)                     |              |
| Spain                                            | 187 (96.9%)                                     | 15 (100%)                     |              |
| Ukraine                                          | 1 (0.52%)                                       | 0 (0.00%)                     |              |
| **Ethnicity**                                     |                                                  |                               |              |
| Caucasian                                        | 191 (98.5%)                                     | 15 (100%)                     |              |
| Native American                                  | 3 (1.5%)                                        | 0 (0.00%)                     |              |
| **Route of infection**                            |                                                  |                               |              |
| IVDA                                             | 136 (68.7%)                                     | 12 (75%)                      |              |
| Sexual                                           | 54 (27.3%)                                      | 4 (25.0%)                     |              |
| Transfusion                                      | 2 (1.01%)                                       | 0 (0.00%)                     |              |
| Unknown                                          | 6 (3.03%)                                       | 0 (0.00%)                     |              |
| **Age at delivery**                              |                                                  |                               |              |
| Years                                            | 34.0 [30.0;37.0]                                | 34.0 [31.5;36.5]              | 0.927        |
| **Gestational age**                              |                                                  |                               |              |
| Weeks                                            | 38.0 [36.0;38.0]                                | 37.5 [36.8;39.0]              | 0.386        |
| **CDC classification**                           |                                                  |                               |              |
| A                                                | 71 (55.9%)                                      | 6 (46.1%)                     |              |
| B                                                | 20 (15.7%)                                      | 4 (30.8%)                     |              |
| C                                                | 36 (28.3%)                                      | 3 (23.1%)                     |              |
| **Immunologic and Virologic status**             |                                                  |                               |              |
| **CD4 before delivery**                          |                                                  |                               |              |
| Count                                            | 542 [374;691]                                   | 456 [336;477]                 | 0.142        |
| %                                                | 31 [21.0;39.6]                                  | 31 [30.0;32.0]                |              |
| **HIV Viral Load before delivery**               |                                                  |                               |              |
| Copies/mL                                        | 50.0 [15.0;200]                                 | 50.0 [15.0;200]               | 1.000        |
| **HIV suppressed at delivery ≤50cp/mL**          |                                                  |                               |              |
| No                                               | 67 (40.4%)                                      | 2 (16.7%)                     | 0.132        |
| Yes                                              | 99 (59.6%)                                      | 10 (83.3%)                    |              |
| **HIV Viral Load at delivery**                   |                                                  |                               |              |
| Copies/mL                                        | 50.0 [50.0;200]                                 | 50.0 [50.0;50.0]              | 0.100        |
| **HCV genotype**                                 |                                                  |                               |              |
| 1                                                | 55 (55.6%)                                      | 6 (75.0%)                     |              |
| 2                                                | 7 (7.07%)                                       | 0 (0.00%)                     |              |
| 3                                                | 19 (19.2%)                                      | 0 (0.00%)                     |              |
| 4                                                | 18 (18.2%)                                      | 2 (25.0%)                     |              |
| **HCV viral load during pregnancy**              |                                                  |                               |              |
| Copies/mL                                        | 2-10⁸ [15.0;700000]                             | 1-10⁶ [6-10⁵; 4.5-10⁶]        | 0.154        |
| **Late presenters** (diagnosed in the third trimester of pregnancy) | | | 1.000        |
| No                                               | 126 (96.9%)                                     | 11 (100%)                     |              |
| Yes                                              | 4 (3.08%)                                       | 0 (0.00%)                     |              |
| **Antiretroviral Treatment**                     |                                                  |                               |              |
| (Continued)                                      |                                                  |                               |              |
In terms of delivery-associated characteristics, there were not consistent differences between HCV transmitters and non-transmitters with regards to the type of delivery or ART (Fig 2). HCV transmission was not associated to HIV viral load (OR: 0.8 [0.46;1.2]), last CD4 count before delivery (OR: 1.1 [0.99;1.1]), or vaginal delivery (OR: 1.63 [0.55;4.62]).

Table 1. (Continued)

| ART before pregnancy | Non-HCV transmitters N = 211 | HCV transmitters N = 16 | $p$-value |
|----------------------|-----------------------------|------------------------|------------|
| No                   | 56 (27.2%)                  | 2 (12.5%)              | 0.521      |
| Yes                  | 146 (70.9%)                 | 13 (81.3%)             |            |
| Unknown              | 4 (1.94%)                   | 1 (6.2%)               |            |

| ART during pregnancy | $p$-value |
|----------------------|------------|
| No                   | 0.605      |
| Yes                  |            |

| Time on ART at delivery | $p$-value |
|-------------------------|------------|
| years                   | 0.148      |

| Delivery                | $p$-value |
|-------------------------|------------|
| Caesarean               | 0.801      |
| Vaginal                 |            |

| HIV prophylaxis in delivery: | $p$-value |
|-----------------------------|------------|
| No                          | 0.305      |
| Yes                         |            |

| Type of newborn prophylaxis: | $p$-value |
|-----------------------------|------------|
| AZT                         | 1.000      |

https://doi.org/10.1371/journal.pone.0230109.t001

Fig 1. CPW non-transmitters mother (grey); CPWHCV transmitters mother (orange):$p$-value.

https://doi.org/10.1371/journal.pone.0230109.g001
Among 227 children included in the study, 16 were vertically HCV infected. All of them had a HCV PCR detected in at least 1 sample and a persistence of HCV antibodies after 18 months of age; thus, the HCV transmission rate from HIV/HCV-coinfected women in this cohort was 7.0 (95%CI 3.7–10.4%).

Newborns vertically HCV infected were similar in gender and physical examination (weight, length, and head circumference) at birth with respect to non-HCV newborns (n = 211). No differences were found between groups (Table 2).
Discussion

HIV influences the progression of HCV disease, including an increased HCV replication, a decreased rate of HCV clearance during acute infection, and accelerated progression to fibrosis. There is some evidence that HIV viral suppression with ART may reduce the risk of HCV transmission in coinfected mothers [17–19], but the evidence to support this hypothesis is scarce.

Our results showed a 7.0 (95%CI 3.7–10.4%) transmission rate, which appears to be lower than the rate reported in the literature previous to the extended use of ART [11,12]. We also found that mothers who gave birth to HCV infected children were similar with respect to all HIV-1 infection features, including viral load or time on ART at delivery. However, HCV viral load during pregnancy was slightly higher in women who transmitted HCV vertically, although no statistical significance was found, probably due to the low sample size. Same effect could be found in the CD4 count before delivery, where we could observe lower values in transmitters mothers.

Our study does not have the power to answer the question if HCV MTCT was lower in HIV/HCV-coinfected mothers due to improved access to ART, since most women received ART, and no comparisons could be made with HIV/HCV women not on ART. Our results may support the hypothesis of lower rates of HCV transmission in the current era as there is an accompanying lower rate of HIV transmission with better maternal HIV infection control during pregnancy. Although the HCV perinatal transmission rate shown in our study of 7.0% is lower than the previously reported in other studies and in a large meta-analysis [11], the broad confidence intervals overlap.

Among risk factors, the majority of studies with scheduled Caesarean delivery in women with HCV infection, with or without HIV coinfection, have found that the procedure does not reduce the risk of perinatal transmission of HCV [20,21]. These data align well with other studies. Neither, female sex, mode of delivery, nor HCV genotype have been factors with a significant association to HCV coinfection in our population.

There is no consensus on the definition of MTCT of HCV. The definitions of HCV infection (ie viremic or non viremic) and of MTCT differ between studies and this may account for some of the variations between MTCT rates between publications. Nevertheless, it is commonly accepted that MTCT of HCV occurs if there is persistence of anti-HCV antibodies in a
child over 18 months of age or the presence of HCV RNA in an infant older than 2 months of age in two different sampling occasions. Since 20% of infants born to HCV infected pregnant mothers may have spontaneous viral clearance, it is important to test for HIV RNA in plasma during the first months of life. Most studies suggest testing for HCV RNA at the age of 2–6 months to early detect HCV infection, along with serum anti-HCV during follow up at 18–24 months in order to verify the persistence or clearance of HCV antibodies [11,12,27]. Since HCV vertical transmission may have a considerable rate of clearance of infection in monoinfected mothers [4] long term follow-up is essential. The proportion of perinatal HCV infected children clearing up the infection has been vaguely studied, and even less data is published in coinfectected children, in whom it appear to be much lower [8]. A late paediatric HCV diagnosis, could increase the risk of adverse events, lead to a secondary transmission and result in higher healthcare costs [22,23].

Although our study shows a HCV MTCT lower than the reported in the pre-ART era, it is consistent with current evidence in coinfectected ART treated women in Europe and USA [24]. Nevertheless, the transmission rate is still high and strategies to further reduce or eliminate any HCV transmission from mother to child should be implemented. The current potent direct-acting antiviral agents (DAA) against HCV offer new options to eliminate any transmission from mother to children. Ideally, HCV infected women should be treated before gestation. When this is not possible, DAA during pregnancy might be an effective approach given that most vertical transmission occurs at the end of pregnancy or during labour and delivery. Considering that HCV RNA levels decline greatly once treatment is started, most women might achieve undetectable HCV RNA near delivery, a key factor in transmission. So far no DAA has been approved for its use during pregnancy, but sofosbuvir and ledipasvir showed promising safety and PK profiles for its potential use in pregnancy, and animal reproductive toxicity data available is reassuring [24] and initial clinical trials in pregnant women are underway [25].

Preterm deliveries proportion in this study (50%) were higher than the reported in this global same cohort (21.5%) [15], probably due to the high proportion of IDVU mother’s route of infection, but without significant differences between HCV transmitters and non-transmitters. However, higher preterm births in HIV/HCV-coinfected mothers than in HIV monoinfected have been reported [(41.1% vs 15.2%), OR: 3.0 (95% CI 1.6, 5.7)] [26].

Limitations of this study included low sample size and the high percentage of missing diagnosis (30%) in children, which means that a significant number of women with a known HCV infection gave birth to children that remain untested. This fact has already been reported in other cohorts [27,28]. However, when analysing differences between HIV/HCV-coinfected women included and not included within the study, scarce differences were found, avoiding the possible selection bias.

Although multi cohort studies with a higher sample size are needed, this is a wide descriptive group that provides an relevant insight in HCV MTCT among HIV/HCV-coinfected women in the ART era. In conclusion, MTCT rates of HCV among HIV/HCV-coinfected women on ART within the Madrid cohort were lower than previously described. However, rates are still significant and strategies to eliminate any HCV transmission from mother to child are needed.

Supporting information
S1 Fig.
(DOCX)
S1 Table. Compared mother-infant pairs with and without HCV available information.

Acknowledgments
Authors would like to acknowledge Santiago Jiménez de Ory (Hospital Gregorio Marañón) for his help in retrieving information for this work and María de la Calle, Talía Saínz (Hospital La Paz), Rafael Rubio García, Federico Pulido, Cristina Epalza (Hospital 12 de Octubre), Isabel Solís, Gabriel Gaspar, Beatriz Soto, (Hospital de Getafe), Pilar Miralles (Hospital Gregorio Marañón), José Sanz, María Penín (Hospital Alcalá de Henares), Miguel Cevero (Hospital de Leganés), Carlos Barros (Hospital de Móstoles), María Jesús Téllez (Hospital Clínico San Carlos), and Juan Emilio Losa (Hospital de Alcorcón) for their work in collecting mothers and children information. We would like to thank for their contributions all children and mothers that get involved in pediatric research and their families.

Author Contributions
Conceptualization: Luis Prieto, María Luisa Navarro-Gómez, José Tomás Ramos Amador.
Data curation: Sara Domínguez-Rodríguez, Carolina Fernández McPhee, Marta Ilán-Ramos, José Beceiro, Luis Escosa, Eloy Muñoz, Iciar Olabarrieta, Francisco Javier Regidor, Miguel Ángel Roa, María del Carmen Viñuela Beneitez, Sara Guillén.
Formal analysis: Sara Domínguez-Rodríguez.
Funding acquisition: María Luisa Navarro-Gómez, José Tomás Ramos Amador.
Investigation: Luis Prieto, Carolina Fernández McPhee, María Luisa Navarro-Gómez, José Tomás Ramos Amador.
Methodology: Sara Domínguez-Rodríguez, José Tomás Ramos Amador.
Project administration: María Luisa Navarro-Gómez, José Tomás Ramos Amador.
Resources: Carolina Fernández McPhee, José Tomás Ramos Amador.
Supervision: José Tomás Ramos Amador.
Validation: José Tomás Ramos Amador.
Writing – original draft: Sara Domínguez-Rodríguez, Luis Prieto, Luis Escosa, Maria Luisa Navarro-Gómez, José Tomás Ramos Amador.
Writing – review & editing: Luis Prieto, Luis Escosa, Maria Luisa Navarro-Gómez, José Tomás Ramos Amador.

References
1. Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun; 4(6):477–487 https://doi.org/10.1016/S2468-1253(19)30046-9 PMID: 30982721
2. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol [Internet]. 2009 May [cited 2018 Jul 11]; 81(5):836–43. Available from: http://doi.wiley.com/10.1002/jmv.21437 PMID: 19319981
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol [Internet]. 2014 Nov 1 [cited 2018 Jul 6]; 61(1 Suppl): S45–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25086286 https://doi.org/10.1016/j.jhep.2014.07.027 PMID: 25086286
1. European Paediatric Hepatitis C Virus Network. A Significant Sex—but Not Elective Cesarean Section
2. Society for Maternal-Fetal Medicine (SMFM) Hepatitis C in pregnancy: screening, treatment, and management.
3. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008. ISBN 3-900051-07-0; 2008.
4. Bortolotti F, Jorio R, Resti M, Cammá C, Marcellini M, Giacchino R, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol [Internet]. 2007 May 1 [cited 2018 Jul 11];46(5):783–90. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168827807000384 https://doi.org/10.1016/j.jhep.2006.12.014 PMID: 17321633
5. Kanninen TT, Dieterich D, Ascuiutti S. HCV vertical transmission in pregnancy: New horizons in the era of DAAs. Hepatology [Internet]. 2015 Dec [cited 2018 Jul 11];62(6):1656–8. Available from: http://doi.wiley.com/10.1002/hep.28032 PMID: 26238474
6. Arshad M, El-Kamary SS, Jhaveeri R. Hepatitis C virus infection during pregnancy and the newborn period—are they opportunities for treatment? J Viral Hepat [Internet]. 2011 Apr [cited 2018 Jul 11];18(4):229–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21392169 https://doi.org/10.1111/j.1365-2893.2010.01413.x PMID: 21392169
7. Muñoz-Gámez JA, Salmerón J, Ruiz-Extremera Á. Hepatitis C during pregnancy, vertical transmission and new treatment possibilities. Med Clin (Barc) [Internet]. 2016 Dec 2 [cited 2018 Jul 11];147(11):499–505. Available from: https://www.sciencedirect.com/science/article/pii/S0022347613630075?via%3Dihub
8. Claret-Teruel G, Noguera-Julian A, Esteva C, Muñoz-Almagro C, Sánchez E, Jiménez R, et al. Impact of Human Immunodeficiency Virus Coinfection on the Progression of Mother-to-child Transmitted Hepatitis C Virus Infection. Pediatr Infect Dis J [Internet]. 2011 Sep [cited 2018 Jul 6];30(9):801–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21772231 https://doi.org/10.1097/INF.0b013e3182196aab4 PMID: 21772231
9. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis. Clin Infect Dis [Internet]. 2014 Sep 15 [cited 2018 Jul 6];49(8):1123–31. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciu447 PMID: 24926290
10. García-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, Pereda-Perez A, Albereola-Cuñat V, López-Hontangas JL, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol [Internet]. 2015 Nov [cited 2018 Jul 6];194:173–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26409061 https://doi.org/10.1016/j.ejogrb.2015.09.009 PMID: 26409061
11. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis. Clin Infect Dis [Internet]. 2014 Sep 15 [cited 2018 Jul 6];49(8):765–73. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciu447 PMID: 24926290
12. Checa Cabot CA, Stoszek SK, Quarleri J, Losso MH, Ivalo S, Peixoto MF, et al. Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women. J Pediatric Infect Dis Soc [Internet]. 2013 Jun 1 [cited 2018 Jul 11];2(2):126–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26199724 https://doi.org/10.1093/jpids/pis091 PMID: 26199724
13. Zuccotti GV, Ribero ML, Giovannini M, Fasola M, Riva E, Portera G, et al. Effect of hepatitis C genotype on mother-to-infant transmission of virus. J Pediatr [Internet]. 1995 Aug 1 [cited 2018 Jul 6];127(2):278–80. Available from: https://www.sciencedirect.com/science/article/pii/S0022347695703098 https://doi.org/10.1016/s0022-3476(95)70309-5 PMID: 7636566
14. Tovo P, Pembrey L, Newell M. A significant sex but not elective caesarean section—effect on mother to child transmission of hepatitis C virus infection. J Infect Dis. 2005; 192:1872–79. https://doi.org/10.1086/515668 PMID: 16267757
15. Prieto LM, González-Tomé MI, Muñoz E, Fernández-Ibíeta M, Soto B, Del Rosal T, et al. Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000–2007. Pediatr Infect Dis J. 2012 Oct; 31(10):1053–8. https://doi.org/10.1097/INF.0b013e31826fe968 PMID: 22926219
16. R Development Core Team. R: A language and environment for statistical computing. Viena, Austria: ISBN 3-900051-07-0; 2008.
17. Papaevangelou V, Pollack H, Rochford G, Kokkia R, Hou Z, Chernew D, et al. Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. J Infect Dis [Internet]. 1998 Oct [cited 2016 Dec 29];178(4):1047–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9806033 https://doi.org/10.1086/515668 PMID: 9806033
18. European Paediatric Hepatitis C Virus Network. A Significant Sex—but Not Elective Cesarean Section—Effect on Mother-to-Child Transmission of Hepatitis C Virus Infection. J Infect Dis. 2005; 192(11):1872–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16267757 https://doi.org/10.1086/497695 PMID: 16267757
19. Society for Maternal-Fetal Medicine (SMFM) Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017; 217(5):B2–B12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28782502 https://doi.org/10.1016/j.ajog.2017.07.039 PMID: 28782502
20. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet (London, England) [Internet]. 2000 Sep 9 [cited 2018 Jul 11];(9233):904–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11036896

21. Mariné-Barjoan E, Berrebi A, Giordanengo V, Favre SF, Haas H, Moreigne M, et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS [Internet]. 2007 Aug 20 [cited 2018 Aug 10]; 21(13):1811–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17690581 PMID: 17690581

22. Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in Children. J Pediatr Gastroenterol Nutr [Internet]. 2006 Aug [cited 2018 Aug 10]; 43(2):209–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16877987

23. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol [Internet]. 2012 Jan 14 [cited 2018 Aug 10]; 18(2):99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22253515 PMID: 22253515

24. Aebi-Popp K, Duppenthaler A, Rauch A, De Gottardi A, Kahlert C. Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. J Virus Erad [Internet]. 2016 Jan 1 [cited 2018 Sep 28]; 2(1):52–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27482435 PMID: 27482435

25. Chappell C. A Phase 1 Pharmacokinetic Trial of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination in Pregnant Women with Chronic Hepatitis C Virus Infection. [cited 2018 Sep 28]; Available from: http://grantome.com/grant/NIH/R21-HD089457-01

26. Benhammou V, Tubiana R, Matheron S, Sellier P, Mandelbrot L, Chenadec J Le, et al. HBV or HCV Coinfection in HIV-1-Infected Pregnant Women in France. JAIDS J Acquir Immune Defic Syndr [Internet]. 2018 Apr 15 [cited 2019 Jan 11]; 77(5):439–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29287028 PMID: 29287028

27. Kuncio DE, Newbern EC, Johnson CC, Viner KM. Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus–Infected Women. Clin Infect Dis [Internet]. 2016 Apr 15 [cited 2018 Aug 10]; 62(8):980–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26797211 PMID: 26797211

28. Delgado-Borrego A, Smith L, Jonas MM, Hall CA, Negre B, Jordan SH, et al. Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. J Pediatr [Internet]. 2012 Nov [cited 2018 Aug 10]; 161(5):915–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22765955 PMID: 22765955